Evidence map›Paper›PMID 35342890›Full record

ArticleAmerican journal of preventive cardiology2022

Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement.

Nathan D Wong, Matthew J Budoff, Keith Ferdinand, Ian M Graham, Erin D Michos, Tina Reddy, Michael D Shapiro, Peter P Toth

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 177 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 6 pooled it
51.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 6 syntheses or guidelines pooled it, 263 citations in OpenAlex.

  1. Methods to assess atherosclerotic cardiovascular risk in chronic respiratory diseases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Sleep duration, blood pressure and cardiovascular outcomes in the middle-aged and the elderly.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. Article

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Nathan D WongHeart Disease Prevention Program, Division of Cardiology, University of California, Irvine, CA, United States.
Matthew J BudoffDivision of Cardiology, Harbor-UCLA Medical Center, Torrance, CA, United States.
Keith FerdinandTulane University Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA United States.
Ian M GrahamDepartment of Cardiology, Trinity College, Dublin, Ireland.
Erin D MichosCiccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Tina ReddyTulane University Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA United States.
Michael D ShapiroDivision of Cardiology, Wake Forest University, NC, United States.
Peter P TothCiccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Johns Hopkins University · USTulane University · USTrinity College Dublin · IEUCLA Medical Center · USUniversity of California, Irvine · USWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk for atherosclerotic cardiovascular disease (ASCVD) shows considerable heterogeneity both in generally healthy persons and in those with known ASCVD. The foundation of preventive cardiology begins with assessing baseline ASCVD risk using global risk scores based on standard office-based measures. Persons at low risk are generally recommended for lifestyle management only and those at highest risk are recommended for both lifestyle and pharmacologic therapy. Additional "risk enhancing" factors, including both traditional risk factors and novel biomarkers and inflammatory factors can be used to further assess ASCVD risk, especially in those at borderline or intermediate risk. There are also female-specific risk enhancers, social determinants of health, and considerations for high-risk ethnic groups. Screening for subclinical atherosclerosis, especially with the use of coronary calcium screening, can further inform the treatment decision if uncertain based on the above strategies. Persons with pre-existing ASCVD also have variable risk, affected by the number of major ASCVD events, whether recurrent events have occurred recently, and the presence of other major risk factors or high-risk conditions. Current guidelines define high to very high risk ASCVD accordingly. Accurate ASCVD risk assessment is crucial for the appropriate targeting of preventive therapies to reduce ASCVD risk. Finally, the clinician-patient risk discussion focusing on lifestyle management and the risks and benefits of evidence-based pharmacologic therapies to best lower ASCVD risk is central to this process. This clinical practice statement provides the preventive cardiology specialist with guidance and tools for assessment of ASCVD risk with the goal of appropriately targeting treatment approaches for prevention of ASCVD events.

Indexed as

ACC, American College of CardiologyAHA, American Heart AssociationASCVD, atherosclerotic cardiovascular diseaseASPC, American Society for Preventive CardiologyBMI, body mass indexCAC, coronary artery calcium, CCTA, coronary computed tomography angiography, CHD, coronary heart diseaseCardiovascular diseaseCKD, chronic kidney diseaseCRP, C-reactive proteinCVD, cardiovascular diseaseDM, diabetes mellitusEAS, European Atherosclerosis SocietyESC, European Society of CardiologyEthnicityFH, familial hypercholesterolemiaGDM, gestational diabetes mellitusIMT, intima media thicknessLDL, low density lipoproteinMMP, matrix metalloproteinaseNHB, non-Hispanic BlackNHW, non-Hispanic WhitePAD, peripheral arterial diseasePCE, pooled cohort equationPCOS, polycystic ovary syndromePOI, premature ovarian insufficiencyPrimary preventionRisk assessmentRisk factors inflammationSDOH, social determinants of healthSecondary preventionSexSubclinical atherosclerosisVTE, venous thrombotic event

Identifiers

PMID35342890
PMCPMC8943256
OpenAlexW4220696966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.